|Bid||174.88 x 100|
|Ask||177.00 x 1000|
|Day's Range||173.25 - 176.42|
|52 Week Range||88.90 - 178.15|
|PE Ratio (TTM)||169.07|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
AstraZeneca, Bristol and Vertex are the likeliest targets of widespread mergers and acquisitions across the biopharma group.
PRA Health Sciences, just voted the Best CRO in Asia, may soon put its new buy point on trial.
The only "problem" mentioned by Vertex CEO Jeff Leiden? It's accumulating cash rapidly.
The major news in the biotech sector in the last five trading sessions include the FDA's refusal to file letter for Celgene Corporation's (CELG) ozanimod while Gilead Sciences, Inc.'s (GILD) announced an agreement with Sangamo Therapeutics.
Vertex could have a tripe-pill regimen in cystic fibrosis as early as 2019, analysts said Thursday after the biotech initiated the first of its Phase 3 studies.
Vertex Pharmaceuticals said Wednesday that the first late-stage trial of a potentially groundbreaking cystic fibrosis drug will be shorter than expected, prompting one analyst to forecast a possible FDA approval as early as the end of next year. Boston-based Vertex (VRTX) said after markets closed on Wednesday that it had launched the first of several Phase 3 studies of a “triple combination” treatment for cystic fibrosis. In a note on Thursday, Leerink Partners analyst Geoffrey Porges said he previously expected the FDA would require four to six months of safety data in a “best-case scenario” for the company, resulting in a possible approval in early 2020.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting VRTX. Over the last one-month, outflows of investor capital in ETFs holding VRTX totaled $1.05 billion.
A trio of investors has identified Vertex Pharmaceuticals, Proofpoint, and Baozun as companies capable of delivering better returns to shareholders from here than the e-commerce giant.
Vertex Pharmaceuticals has unveiled promising findings from a study of one of its experimental drugs — only this time, the treatment doesn’t target cystic fibrosis. Boston-based Vertex (VRTX), which largely focuses on the lung disorder, said Wednesday that its non-opioid medicine for pain had performed well in a mid-stage study. Patients who received the drug, called VX-150, following surgery to remove bunions reported significant pain relief compared to those on placebo, according to the company.
Payers likely won't balk at the yearly price for Vertex's new two-drug regimen to treat some cystic fibrosis patients, analysts said Tuesday.
Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment.